Primary biliary cholangitis: Disease burden, treatments and RWD gaps
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic...
Regulatory decision-making depends on evidence that reflects how medical products perform in real-world use, not only in controlled trials. For more than a decade, the Food and Drug Administration has relied on real-world data and real-world...
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic...
HealthVerity Audiences Healthcare marketing has reached an inflection point and for years, success...
Capturing the true complexity of psoriasis in the real world Psoriasis is a common chronic...
Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Artificial intelligence is no longer something healthcare and life sciences teams are testing on...
Regulatory decision-making depends on evidence that reflects how medical products perform in...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Early signals indicate continued declines in influenza vaccination uptake and shifts in the...
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease marked by immune-mediated damage to the small bile ducts inside the liver. Over time, that injury can lead to cholestasis (reduc...